source
- Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early dataPfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026. The results indicated the drug was effective in patients who have both obesity and d…
- Roche to launch Phase 2 trial of petrelintide and enicepatide combination for obesityRoche announced it will begin a Phase 2 study this year testing a combination of its two obesity candidates, petrelintide and enicepatide. The company describes petrelintide as having a potentiall…